Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 3, 2006, Pages 479-490

  Scaglione, Francesco ^a   Paraboni, Luca ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

lactams; Aminoglycosides; AUC MIC ratio; Azalides; Cmax MIC ratio; Clinical efficacy; Dosing regimens; Fluoroquinolones; Glycopeptides; Ketolides; Macrolides

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; DORIPENEM; ERTAPENEM; FLUCONAZOLE; FROPENEM; GENTAMICIN; GLYCYLCYCLINE DERIVATIVE; IMIPENEM; KETOLIDE; LINEZOLID; MACROLIDE; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DEGRADATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PHARMACODYNAMICS; REVIEW; THROMBOPHLEBITIS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FLUOROQUINOLONES; GLYCOPEPTIDES; HUMANS; KETOLIDES; MACROLIDES;

EID: 33745218049     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.3.479     Document Type: Review

References (106)

1. Schaper KJ, Schubert S, Dalhoff A. Kinetics and quantification of antibacterial effects of β-lactams, macrolides, and quinolones against Gram-positive and Gram-negative RTI pathogens. Infection 33(Suppl. 2), S3-S14 (2005).
2. Craig WA, Suh B. Protein binding and the antimicrobial effects: methods for the determination of protein binding. In: Antibiotics in Laboratory Medicine. Lorian V (Ed.), Williams and Wilkins, MD, USA, 367-402 (1991).
3. Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo. J. Antimicrob. Chemother. 11, 233-238 (1983).
4. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamic: a critical review. Int. J. Antimicrob. Agents 19, 261-268 (2002).
5. Craig WA. Pharmacokinetic/pharmacodynamic indices: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1-12 (1998).
6. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Sarptococcus pneumoniae. application to breakpoint determinations. Antimicrob. Agents Chemother. 42, 2375-2379 (1998).
7. Scaglione F, Mouton JW, Mattina R, Fraschini F. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob. Agents Chemother. 47, 2749-2755 (2003).
8. Craig WA, Dalhoff A. Pharmacodynamics of fluoroquinolones in experimental animals. In: Handbook of Experimental Pharmacology: Quinolone Antibacterials. Vol. 127. Kulman J, Dalhoff A, Zeiler HJ (Eds). Springer-Verlag Berlin, Heidelberg, Germany, 207-232 (1998).
9. Craig WA. Postantibiotic effects and the dosing of macrolides, azalides, and streptogramins. In: Expanding Indications for the New Macrolides, Azalindes and Streptogramin. Zinner SH, Young LS, Acar JF, Neu HC (Eds), Marcel Dekker, NY, USA, 27-38 (1997).
10. Craig WA. Does the dose matter? Clin. Infect Dis. 33(Suppl. 3), S233-S237 (2001).
11. Drusano GL. Prevention of resistance: a goal for dose selection of antimicrobial agents. Clin. Infect. Dis. 36(Suppl. 1), S42-S50 (2003).
12. Turnidge JD. The pharmacodynamics of β-lactams. Clin, Infect. Dis. 27, 10-22 (1998).
13. Craig WA. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J. 77(Suppl. 6), S7-S11 (1998).
14. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Infect. Dis. Clin. North Am. 12(4), 849-860 (1998).
15. Mouton JW, Punt N. Use of the T>/MIC to choose between different dosing regimens of β-lactam antibiotics. J Antimicrob. Chemother. 47(4), 500-501 (2001).
16. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin. Pharmacokinet. 39(3), 185-201 (2000).
17. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. 15, 255-259 (1996).
18. Heffelfinger JD, Dowell SF, Jorgensen JH et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae therapeutic working group. Arch. Intern. Med. 160, 1399-1408 (2000).
19. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22, 89-96 (1995).
20. Craig WA, Ebert S, Watanabe Y. Differences in time above MIC required for efficacy of β-lactams in animal infection models. Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). American Society for Microbiology, Washington, DC, USA, Abstract 86 (1993).
21. Navarro AS. New formulation of amoxicillin/clavulanic acid. A pharmacokinetic and pharmacodynamic review Clin. Pharmacokinet. 44(11), 1097-1115 (2005).
22. Craig WA. Proof of concept: performance testing in models. Clin. Microb. Infect. 10 (Suppl. 2), S12-S17 (2004).
23. Dagan AR, Klugman KP, Craig WA Baquero AF. Evidence to support the rationale that bacterial eradication in respiratory tract infections is an important aim of antimicrobial therapy. J. Antimicrob. Chemother: 47, 129-140 (2001).
24. Vondracek TG. β-lactam antibiotics: is continuous infusion the preferred method of administration? Ann. Pharmacother. 29, 415-424 (1995).
25. Nightingale CH, Quintilliani R, Nicolau DP. Intelligent dosing of antimicrobials. In: Current Clinical Topics in Infectious Disease, vol. 14. Remington SC, Swartz MN (Eds), Blackwell Scientific Publishers (1994).
26. Bodey GP. Ketchel SJ, Rodriguez VA. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am. J. Med 67, 608-616 (1979).
27. MacGowan AP, Bowker KE. Continuous infusion of β-lactam antibiotics. Clin. Pharmacokinet. 35, 391-402 (1998).
28. Angus BJ, Smith D, Suputtamongkol Y et al. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs. intermittent bolus injection in septicaemic melioidosis. Br. J. Clin. Pharmacol. 49, 445-452 (2000).
29. Egerer G, Goldschmidt H, Salwender H et al. Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high dose chemotherapy and peripheral blood stem transplantation. Int. J. Antimicrob. Agents 15, 119-123 (2000).
30. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int. J. Antimicrob. Agents 17, 497-504 (2001).
31. Frei CR, Burgess DS. Continuous infusion β-lactam for intensive care unit pulmonary infections. Clin. Microbiol. Infect. 11 (5), 418-421 (2005).
32. Kuti JL, Nightingale CH, Quintiliani R et al. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn. Microbiol. Infect. Dis. 44, 51-57 (2002).
33. Vinks AA, den Hollander JG, Overbeek SE et al. Population pharmacokinetic analysis of nonlinear behaviour of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob. Agents Chemother. 47, 541-547 (2003).
34. Buck C, Bertram N, Ackermann T, Paar WD. Phatmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion Int. J. Antimicrob. Agents 25, 62-67 (2005).
35. Munckoff WJ, Carney J, Neilson G, Whitby M. Continuous infusion of ticarcillin-clavulanate for home treatment of serious infection: clinical efficacy, safety, pharmacokinetics and pharmacodynamics Int. J. Antimicrob. Agents 25, 514-522 (2005).
36. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect, Dis, 5, 581-589 (2005).
37. Baririan N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J. Antimicrob. Chemother. 51, 651-658 (2003).
38. Dalhoff A, Janjic N, Echols R. Redefining penems. Biochem. Pharmacol. 71, 1085-1095 (2006).
39. Bustamente CI, Drusano GL, Tatem BA, Standiford HC. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 26, 678-682 (1984).
40. Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. PharmacoEconomics 20, 513-528 (2002).
41. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Role of pharmacodynamics in designing dosage regimens for β-lactams. Conn. Med. 67, 265-268 (2003).
42. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin. Therapeutics 26(8), 117-1198 (2004).
43. Viaene E, Chanteux H, Servais H et al. Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob. Agents Chemother. 46, 2327-2332(2002).
44. Thalhammer F, Traunmuller F, El Menyawi I et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J. Antimicrob. Chemother. 43, 523-527 (1999).
45. Grant EM, Zhong MK, Ambrose PG et al. Stability of meropenem in a portable infusion device in a cold pouch. Am. J. Health Syst. Pharm. 57, 992-995 (2000).
46. Kuti JL, Nightingale CH, Knauft RF Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis Clin. Therapeutics 26(4), 493-501 (2004).
47. Maglio D, Nightingale CH, Nicolau DP. Extended interval aminoglycoside dosing: from concept to clinic Int. J. Antimicrob. Agents 19, 341-348 (2002).
48. Noone P, Pattison JR. The effective use of gentamicin in life threatening sepsis. Postgrad. Med. 50(Suppl. 4), S9-S16 (1974).
49. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am. J. Med. 77, 657-662 (1984).
50. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia, J. Infect. Dis. 149, 443-448 (1984).
51. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155, 93-99 (1987).
52. Craig WA, Leggett J, Totsuka K, Vogelman B. Key pharmacokinetic parameters of antibiotic efficacy in experimental animal infections. J. Drug Dev. 1 (Suppl. 3), S7-S15 (1988).
53. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect Control. Hosp. Epidemiol. 11, 319-326 (1990).
54. Giuliano RA, Verpooten GA, Verbist L, Wedeen R, De Broe ME. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J. Pharmacol. Exp. Ther. 236, 470-475 (1986).
55. Bennett WM, Plamp CE, Gilbert DN, Parker RA, Porter GA. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J. Infect, Dis. 140, 576-580 (1979).
56. De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J. Antimicrob. Chemother. 27(Suppl. C), S41-S47 (1991).
57. LeBrun M, Grenier L, Gourde P et al. Effectiveness and toxicity of gentamicin in an experimental model of pyelonephritis: effect of the time of administration. Antimicrob. Agents Chemother, 43, 1020-1026 (1999).
58. Prins JM, Weverling GJ, van Ketel RJ et al. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Clin. Pharmacol. Ther. 62, 106-111 (1997).
59. Brummett RE. Ototoxicity of aminoglycoside antibiotics in animal models. INSERM 102, 359-376 (1982).
60. Tran Ba Huy P, Deffrennes D. Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features. Acta. Otolaryngol. 105, 511-515 (1988).
61. Preston SL, Drusano GL, Berman AL et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. J. Am. Med. Assoc. 279(2), 125-129 (1998).
62. Drusano GL. Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome. J. Chemother. 12(Suppl. 4), S21-S26 (2000).
63. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37, 483-490 (1993).
64. Peloquin CA, Cumbo TJ, Nix DE, Sands MF, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch. Intern. Med. 149, 2269-2273 (1989).
65. Lee BL, Padula AM, Kimbrough RC et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N. Engl. J. Med. 325, 520-521 (1991).
66. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37, 1073-1081 (1993).
67. Ambrose PG, Bhavnani SM, Owens RC. Clinical pharmacodynamics of quinolones. Infect. Dis. Clin. North Am. 17, 529-543 (2003).
68. Jones RN, Rubino CM, Bhavnani SM, Ambrose PG. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae, report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob. Agents Chemother. 47, 292-296 (2003).
69. Owens RC, Bhavnani SM, Ambrose PG. Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 51, 45-49 (2005).
70. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin. Microbiol. Infect. 7, 589-596 (2001).
71. Zhao X, Drlica K. Restricting the selection of antibiotic resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl. 3), S147-S156 (2001).
72. Firsov AA, Vostrov SN, Lubenko IY et al. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 1604-1613 (2003).
73. Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob. Agents Chemother. 46, 522-524 (2002).
74. Zinner SH, Lubenko IY, Gilbert D et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing J. Antimicrob. Chemother. 52, 616-622 (2003).
75. Goldman RC, Scaglione F. The macrolide - bacterium interaction and its biological basis. Curr. Drug Targets Infect. Disord. 4(3), 241-260 (2004).
76. Craig WA. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy. Respir. Med. 95(Suppl. A), S12-S19 (2001).
77. Craig WA, Keim S, Andes DR. Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, Abstract A-1264 (2002).
78. Babl FE, Pelton SI, Li Z. Experimental acute otitis media due to non typeable Haemophilus influenzae: comparison of high and low azithromycin doses with placebo. Antimicrob. Agents Chemother. 46, 2194-2199 (2002).
79. Cohen R, Reinert P, de la Rocque F et al. Comparison of two dosages of azithromycin for three days versus penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. Pediatr: Infect. Dis. J. 21, 297-303 (2002).
80. Casey JR, Pichichero ME. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. Clin. Infect. Dis. 40, 1748-1755 (2005).
81. Arguedas A, Emparanza P, Schwartz RH, Soley C, Guevara S, de Caprariis PJ. A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. Pediatr. Infect. Dis.J. 24(2), 153-161 (2005).
82. Soley CA, Arguedas A. Single-dose azithromycin for the treatment of children with acute otitis media. Expert. Rey Anti Infect. Ther. 3(5), 707-717 (2005).
83. Drehobt MA, De Salvo MC, Lewis DE, Breen JD. Single-dosea zithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 128(4), 2230-2237 (2005).
84. Murray JJ, Emparanza P Lesinskas E, Tawadrous M, Breen JD. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. Otolaryngol. Head Neck Surg. 133(2), 194-200 (2005).
85. Amsden GW, Nafziger AN, Foulds G. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1500 milligrams, given over a 3-or 5-day period in healthy subjects. Antimicrob. Agents Chemother. 43, 163-165 (1999).
86. Van Bambeke F, Tulkens PM. Macrolides: pharmacokinetics and pharmacodynamics. Int. J. Antimicrob. Agents 18 (Suppl. 1), S17-S23 (2001).
87. Ackermann G, Rodloff AC. Drugs of the 21st century: telithromycin (HMR 3647) the first ketolide J. Antimicrob. Chemother. 51, 497-511 (2003).
88. Contrepois A, Joly V, Abel L et al. The pharmacokinetics and extravascular diffusion of teicoplanin in rabbits and comparative efficacy with vancomycin in an experimental endocarditis model. J. Antimicrob. Chemother. 21, 621-631 (1988).
89. Chambers HF, Kennedy S. Effect of dosage, peak and trough concentrations in serum, protein binding and bactericidal rate of efficacy of teicoplanin in a rabbit model with endocarditis. Antimicrob. Agents Chemother. 34, 510-514 (1990).
90. MacGowan A, White L, Reeves D et al. Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. J. Infect. Chemother. 2, 197-208 (1996).
91. Pea F, Brollo L, Viale P, Pavan F, Furlanut M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J. Antimicrob. Chemother. 51(4), 971-975 (2003).
92. Pea F, Viale P, Candoni A et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin. Pharmacokin. 43(6), 405-415 (2004).
93. Zimmerman AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcome in patients with Gram-positive bacteraemia. Pharmacotherapy 15, 85-91 (1995).
94. Mulhern JG, Braden GL, O'Shea MH et al. Trough serum vancomycin levels predict the relapse of gram-positive peritorritis in peritoneal dialysis patients. Am. J. Kidney Dis. 25, 611-615 (1995).
95. Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann. Pharmacother 28, 1335-1339 (1994).
96. Fernandez de Gatta MD, Calvo MV, Hernandez JM et al. Cost effectiveness analysis of serum vancomvcin concentration monitoring in patients with haematologic malignancy. Clin. Pharmacol. Ther. 60, 332-340 (1996).
97. Karam CM, McKinnon PS, Neuhauser MM, Rybak MJ. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy 19(3), 257-266 (1999).
98. Ebert S. In vivo cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and -resistant S. aureus. Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (New York). American Society for Microbiology, Washington, DC, USA, 173, Abstract 439 (1987).
99. Knudsen JD, Fuursted K, Espersen F, Frimodt-Moller N. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrob. Agents Chemother 41, 1910-1915 (1997).
100. Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Møller N. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Atimicrob. Agents Chemother. 44(5), 1247-1254 (2000).
101. Iwamoto T, Kagawa Y, Kojma M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol. Pharm. Bull. 26(6), 876-879 (2003).
102. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42(Suppl. 1), S35-S39 (2006).
103. Rybak MJ, Cappelletty DM, Ruffing MJ et al. Influence of vancomycin serum concentrations on the outcome of patients being treated for gram-positive infections. Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). American Society for Microbiology, Washington, DC, USA, 9, Abstract A-46 (1997).
104. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43, 925-942 (2004).
105. Drew RH, Lu I, Joyce M, Benjamin DK Jr, Fowler VG Jr. Lack of relationship between predicted area under the time-concentration curve/ minimum inhibitory concentration and outcome in vancomycin-treated patients with Staphylococcus aureus bacteremia. Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA, 36, Abstract A-1493 (2004).
106. Scaglione F. Can PK/PD be used in everyday clinical practice. Int. J Antimicrob. Agents 19(4), 349-353 (2002).